Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neuroendocrine Tumors
Pancreatic Neoplasms
Protein Kinase Inhibitors
Sirolimus
TOR Serine-Threonine Kinases
Vascular Endothelial Growth Factor A
authors with profiles
Hedy Kindler